The protein target Mfa1 in periodontics: molecular mechanism and antibacterial intervention strategy

Research has shown that blocking a key bacterial appendage can prevent plaque formation, gum inflammation, and associated complications. The ability of Porphyromonas gingivalis to colonize the oral cavity largely depends on a short surface filament that helps the pathogen attach to other bacteria, establish itself within biofilms, and evade recognition by the host immune system.

Mechanism of Mfa filament formation and potential therapeutic targets

A new study conducted in Japan has elucidated the mechanism of filament formation and identified several potential targets for therapeutic intervention. The filament, known as Mfa pilus, consists of multiple copies of the Mfa1 protein. Scientists found that even minor alterations at one end of Mfa1 prevent filament formation, which theoretically could limit the ability of P. gingivalis to colonize.

The role of calcium in immune surveillance evasion

A separate region of the filament serves to evade immune surveillance. When the ability of this region to bind calcium was disrupted, cultured human cells demonstrated an enhanced inflammatory response — indicating that calcium binding facilitates the pathogen’s escape from innate immunity. The obtained data open new perspectives for the development of antimicrobial agents that disrupt the pathogen’s evasive mechanisms.

Interaction with commensal microbiota and formation of polymicrobial biofilms

Researchers identified the localization and structure of the Mfa1 region responsible for binding to the surface protein of Streptococcus gordonii — an early colonizer of tooth surfaces. Since this interaction promotes the development of polymicrobial biofilms, the obtained data may serve as a basis for the development of molecules that disrupt bacterial adhesion and prevent biofilm maturation at early stages of its formation.

Experimental evidence of efficacy and translational potential

The prospects for therapeutic application are supported by recent studies: antibodies against Mfa1 reduce bacterial load and alveolar bone loss in rat experiments. Given the growing evidence base on the association of P. gingivalis with systemic diseases — including cardiovascular disease, diabetes mellitus, and Alzheimer’s disease — drugs developed on the basis of these results may have significance beyond dentistry and open possibilities for the prevention and treatment of systemic complications of periodontal infection.

Source

Original publication